Skip to main content
ProMIS Neurosciences Inc. logo

ProMIS Neurosciences Inc. — Investor Relations & Filings

Ticker · PMN ISIN · CA74346M1095 LEI · 5299007HZF79F9IAXI53 US Professional, scientific and technical activities
Open in API
Filings indexed 333 across all filing types
Latest filing 2024-08-02 Director's Dealing
Country CA Canada
Listing US PMN

About ProMIS Neurosciences Inc.

https://www.promisneurosciences.com/

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company focused on the discovery and development of selective antibody therapeutics for neurodegenerative and other misfolded protein diseases. The company leverages a proprietary technology platform to design and generate antibodies that selectively target toxic oligomers, which are key drivers of diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS), Parkinson’s disease (PD), and multiple system atrophy (MSA). Its lead product candidate, PMN310, is in clinical development for Alzheimer's disease. The company's approach aims to provide effective treatments while potentially reducing side effects associated with less specific therapies.

Recent filings

Filing Released Lang Actions
OWNERSHIP DOCUMENT
Director's Dealing
2024-08-02 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The content specifically discusses the company regaining compliance with NASDAQ listing requirements related to market value of listed securities. There is no detailed financial data, earnings information, or management discussion. The document is relatively short (3263 characters) and serves as a regulatory announcement about compliance status rather than a full financial report or earnings release. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2024-07-29 English
8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated July 26, 2024, by ProMIS Neurosciences Inc. It details the entry into a material definitive agreement related to a private investment in public equity (PIPE) financing, including the sale of common share units and warrants, the terms of the offering, and related registration rights. The document also includes information about the unregistered sale of equity securities and a press release announcing the pricing of the offering. The content focuses on a capital raising transaction and financing activities, not on financial results, management changes, or other report types. Therefore, this filing is best classified as a Capital/Financing Update (CAP). The document length is over 10,000 characters and contains substantive details about the financing, not just an announcement or reference to a report, so it is not an RPA or RNS. Confidence is high due to the clear focus on financing terms and agreements.
2024-07-26 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC by ProMIS Neurosciences Inc. dated July 26, 2024. It announces positive data from the first four cohorts of a Phase 1a clinical trial and includes a press release as an exhibit. The content focuses on clinical trial results and forward-looking statements rather than detailed financial data or comprehensive management discussion. The document is a regulatory announcement of an event rather than a full financial report or earnings release. It does not fit into categories like Annual Report, Earnings Release, or Management Reports. Given it is a regulatory filing reporting material events and disclosures, the most appropriate classification is Regulatory Filings (RNS). The document length (8894 characters) and content support this classification with high confidence.
2024-07-26 English
8-K
Delisting Announcement Classification · 95% confidence The document is a Form 8-K current report filed with the SEC by ProMIS Neurosciences Inc. dated July 2, 2024. The content describes receipt of a notice from Nasdaq regarding non-compliance with a listing rule due to the company's market value falling below the minimum required threshold. It details the company's compliance period and potential delisting consequences. This is a regulatory announcement about the company's listing status, specifically a notice of potential delisting. The document is not a full financial report, audit, or earnings release, but an official notice related to stock exchange listing status. Therefore, it fits the category of a Delisting Announcement (DLST). The document length is under 5,000 characters and contains substantive information about the delisting notice, not just a report publication announcement or certification. Hence, the classification is DLST with high confidence.
2024-07-05 English
8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a Form 8-K current report filed with the SEC by ProMIS Neurosciences Inc. dated June 13, 2024. The key content is the submission of matters to a vote of security holders at the company's 2024 annual meeting, including detailed voting results for director elections, ratification of auditors, and stock option approvals. This matches the description of a Declaration of Voting Results & Voting Rights Announcements, which reports official results from shareholder votes at a general meeting. The document is not an Annual Report, Audit Report, or Proxy Statement, but specifically reports voting outcomes. The length (5824 characters) and detailed vote counts confirm it is the voting results report itself, not just an announcement of a report. Therefore, the correct classification is DVA (Declaration of Voting Results & Voting Rights Announcements).
2024-06-14 English

Browse filings by year

21 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.